Acquisitions and Investments - The Company completed the acquisition of dp polar for 25.2million,whichincludes19.6 million in cash and 7.1millionincommonstock,aimedatenhancinghigh−speedmassproductioncapabilities[122].−TheacquisitionofKumovisfor37.9 million focuses on utilizing PEEK materials for medical applications, with 3.6milliondeferredforuptofifteenmonths[123].−Titanwasacquiredfor39.0 million to address large build volume applications in the Industrial Solutions segment, with the acquisition's near-term impact being dilutive [124]. - A joint venture with the Saudi Arabian Industrial Investments Company was established to expand additive manufacturing in Saudi Arabia, with an initial investment of approximately 6.5million[126].−TheCompanyinvested10.0 million for a 26.6% stake in Enhatch Inc., aimed at streamlining the design and delivery of patient-specific medical devices [127]. - The acquisition of Volumetric Biotechnologies for 40.2millionaimstodevelopbioprintingtechnologiesforhumanorgans,withpotentialadditionalpaymentsofupto355.0 million based on milestones [128]. - The acquisition of Oqton for 187.8millionenhancestheCompany′ssoftwarecapabilitiesinmanufacturingoperationssystems,withadilutiveimpactonfinancialresults[129].−Dussurand3DSystemsformedajointventureinMarch2022toenhanceadditivemanufacturinginSaudiArabia,withaninitialinvestmentofapproximately6.5 million [187]. - As of March 31, 2023, the company holds 49% of the joint venture's common stock, with 3.4millioninescrowandanadditional3.1 million deposited for operations [187]. - Future investments in the joint venture are contingent upon achieving specific milestones [187]. Financial Performance - Total revenue for the three months ended March 31, 2023, was 121.236million,adecreaseof11.8 million or 8.8% compared to 133.001millionforthesameperiodin2022[148].−Productsrevenuedecreasedby16.2 million or 16.1% to 84.388million,primarilyduetoa19.1 million decrease in sales volume within the Healthcare Solutions segment [146]. - Services revenue increased by 4.4millionor13.536.848 million, driven by higher sales volume in both Healthcare Solutions and Industrial Solutions segments [147]. - Gross profit for the three months ended March 31, 2023, was 47.098million,down6.697 million or 12.4% from 53.795millioninthesameperiodin2022[149].−OperatinglossforthethreemonthsendedMarch31,2023,was33.396 million, compared to a loss of 23.232millionforthesameperiodin2022[154].−Netlossattributableto3DSystemsCorporationforthethreemonthsendedMarch31,2023,was29.421 million, compared to a net loss of 26.799millionforthesameperiodin2022[158].−AdjustedEBITDAdecreasedfrom1.923 million for the three months ended March 31, 2022, to (10.094)millionforthesameperiodin2023,primarilyduetoanincreaseinoperatingloss[160].−Selling,generalandadministrativeexpensesincreasedby2.9 million or 5.2% to 58.285million,influencedbyacquisitionsandhigherprofessionalservicesfees[153].−Researchanddevelopmentexpensesincreasedby0.6 million or 2.8% to 22.209million,primarilyduetoexpensesrelatedtoacquisitions[153].−Interestandotherincome,netforthethreemonthsendedMarch31,2023,was3.875 million, compared to a net expense of (2.283)millionforthesameperiodin2022[155].−ForthethreemonthsendedMarch31,2023,thecompanyreportedanetlossof29.4 million, compared to a net loss of 26.8millionforthesameperiodin2022[163].−Totalrevenueforthecompanydecreasedby11.8 million, or 8.8%, from 133.0millioninQ12022to121.2 million in Q1 2023 [166]. - Healthcare Solutions revenue decreased by 15.6million,or24.310.7 million, or 67.9%, driven by decreased revenue and a 2.5millionincreaseinoperatingexpenses[168].−IndustrialSolutionsrevenueincreasedby3.9 million, or 5.6%, with a 9.8% increase in sales volumes, partially offset by foreign exchange impacts [169]. - Adjusted EBITDA for Industrial Solutions increased by 0.3million,or5.1137.8 million, or 35.5%, from 388.1millionatDecember31,2022,to525.9 million at March 31, 2023 [174]. - Cash used in operating activities was 27.7millionforQ12023,anincreaseof12.6 million compared to 15.1millioninQ12022[181].−Cashprovidedbyinvestingactivitieswas167.8 million in Q1 2023, primarily from proceeds of 176.9millionfromsalesandmaturitiesofshort−terminvestments[182].−Thecompanyhad460 million of outstanding 0% convertible notes maturing in November 2026, with potential for additional long-term financing [185]. - The company believes it has sufficient financial resources to meet cash requirements for the next twelve months, dependent on profitability and working capital management [188]. - The company is in compliance with all covenants of the outstanding 0% convertible notes due November 2026 as of March 31, 2023 [189]. Risks and Internal Controls - Forward-looking statements are subject to risks including geopolitical events, supply chain disruptions, and the ability to meet customer needs [194]. - The company emphasizes the importance of maintaining effective internal controls over financial reporting and managing product inventory [195]. - The company has directors' and officers' insurance coverage to mitigate potential indemnification obligations [190]. - There were no material changes in market risk assessment from December 31, 2022, to March 31, 2023 [197]. - There have been no changes to critical accounting estimates that materially impact the financial statements as of the report date [192].